Sartorius (ETR:SRT) Given a €96.00 Price Target by HSBC Analysts

Share on StockTwits

Sartorius (ETR:SRT) has been given a €96.00 ($111.63) price objective by equities researchers at HSBC in a research note issued to investors on Wednesday, July 25th. The firm currently has a “sell” rating on the stock. HSBC’s price target would indicate a potential downside of 24.71% from the stock’s previous close.

A number of other research analysts have also recently issued reports on the company. Berenberg Bank set a €110.00 ($127.91) price objective on Sartorius and gave the company a “neutral” rating in a report on Friday, May 25th. Deutsche Bank set a €125.00 ($145.35) price objective on Sartorius and gave the company a “neutral” rating in a report on Friday, July 13th. Commerzbank set a €100.00 ($116.28) price objective on Sartorius and gave the company a “sell” rating in a report on Friday, June 15th. Warburg Research set a €141.00 ($163.95) price objective on Sartorius and gave the company a “neutral” rating in a report on Monday, May 28th. Finally, Kepler Capital Markets set a €78.00 ($90.70) price objective on Sartorius and gave the company a “neutral” rating in a report on Tuesday, July 24th. Four investment analysts have rated the stock with a sell rating and four have given a hold rating to the stock. The company presently has an average rating of “Hold” and an average price target of €114.88 ($133.58).

Shares of ETR SRT traded down €0.50 ($0.58) during midday trading on Wednesday, reaching €127.50 ($148.26). 37 shares of the company traded hands.

Sartorius Company Profile

Sartorius Aktiengesellschaft provides pharmaceutical and laboratory equipment worldwide. The company operates through two divisions, Bioprocess Solutions, and Lab Products & Services. The Bioprocess Solutions division offers products, technologies, and services ranging from fermentation, cell cultivation, filtration, and purification to media storage and transportation for the biopharmaceutical industry.

Further Reading: Analyst Ratings

Analyst Recommendations for Sartorius (ETR:SRT)

Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.